Usama Gergis, MD
Hematology & Oncology · Allentown, PANPI 1548450984
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $919,908 of the $1,163,421 with a category attached, or 79.1%. 22 manufacturers reported payments, led by Incyte Corporation at 38.2% of the total. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,081 payments — averaging $1076.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$444K
- Jazz Pharmaceuticals Inc.$276K
- Astellas Pharma US Inc$200K
- Gilead$191K
- Merck$28K
- E.r. Squibb & Sons, L.L.C.$7K
- plus $17K from 16 others
Across 133 payments — averaging $15,939 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$936K
- Novartis$354K
- Janssen Research & Development, LLC$308K
- Jazz Pharmaceuticals Inc.$262K
- Takeda Pharmaceuticals U.S.A., Inc.$235K
- E.r. Squibb & Sons, L.L.C.$15K
- plus $10K from 1 others
What the payments were for
- Consulting fees$74,2116%
- Speaking & faculty fees$919,90879%
- Travel & lodging$146,64413%
- Food & beverage$22,5772%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 479 | $444,120 |
| Jazz Pharmaceuticals Inc. | 208 | $275,640 |
| Astellas Pharma US Inc | 165 | $199,899 |
| Gilead | 155 | $191,141 |
| Merck | 20 | $28,153 |
| E.r. Squibb & Sons, L.L.C. | 3 | $7,266 |
| Novartis | 12 | $5,481 |
| Autolus Inc | 4 | $5,391 |
| National Marrow Donor Program | 11 | $3,400 |
| Gamida Cell Inc.(2 entities) | 2 | $1,827 |
| Bristol Myers Squibb | 6 | $304 |
| AbbVie | 1 | $144 |
| Stemline Therapeutics Inc. | 2 | $125 |
| Iovance Biotherapeutics, Inc. | 1 | $123 |
| Biolinerx USA, Inc. | 1 | $119 |
| Kadmon Pharmaceuticals LLC | 1 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Pfizer | 3 | $58 |
| Legend Biotech USA Inc. | 1 | $45 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Johnson & Johnson | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,163,421 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Allentown
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
- Hashem YounesPittsburgh$435K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.